first look math hard temporari
disappoint couldnt get full set financi time
report encourag compani solid perform close
given signific tax law chang us end year
incred complex tax structur concern delay appreci
compani effort give top-lin financi perform said think current
weak share creat buy opportun ahead releas
compani full financi initi guidanc reiter buy rate
tax law chang like creat issu year-end close state
need addit time complet final incom tax review procedur relat
reconcili specif non-cash item order report result given recent
tax law chang complex tax structur follow invers
delay concern us delay last year caus tysabri royalti
sale share similarli pressur rebound compani
eventu releas financi short order
revenu mm cgie mm consensu mm
within consum healthcar america chca revenu mm
mm estim consensu mm consum healthcar chci
post mm revenu mm expect consensu
mm prescript revenu mm line mm
expect consensu mm
reiter buy rate pt reiter buy rate price target
share continu see uniqu consumer-gener hybrid capabl
continu single-digit top-lin growth new product launch macro privat
label trend us over-the-counter busi coupl modest growth ou
brand over-the-counter busi new launch geograph ration
perrigo compani plc focus develop
distribut private-label gener brand over-the-counter
prescript drug private-label nutrit product
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
beat driven core perform tax repo
chang estim
weve updat model reflect preliminari perform
price target deriv blend dcf wacc termin
growth lead valuat weight around forward
ev/ebitda gener group averag estim lead
valuat weight around
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand compani
